Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Antibody–lectin chimeras (AbLecs) are an immunotherapy modality designed to bind and block glycans that contribute to immune suppression in cancer. AbLecs enhance antitumor immune responses both in vitro and in vivo, outperforming conventional antibody therapies, including approved cancer drugs.
This pioneer in programmable biology creates new methods for the computer science and bioengineering communities and translates those advances to try to solve some of the most fundamental problems facing our world.
In-body manufacturing promises a faster, cheaper and simpler alternative to CAR-T cell therapy — if the field can deliver clinical readouts that prove long-term safety and efficacy.
